Okeiro, a precision medicine company focused on transplantation and chronic disease management, has announced the successful closing of a €10 million funding round. The investment — led by Alven, Forepont Capital Partners, and Red River West — will enable the company to accelerate its growth in France and expand internationally. Okeiro is developing cutting-edge clinical decision support tools that leverage AI to prevent organ failure, particularly in kidneys, lungs, hearts, and livers. With kidney disease alone affecting over 850 million people globally and representing 70% of all transplants, the company’s mission addresses a pressing and growing medical need.
At the heart of Okeiro’s platform is the iBox algorithm, a predictive AI model that has been clinically validated and approved by both the FDA and EMA as a surrogate endpoint in clinical trials. Developed in partnership with APHP and INSERM, France’s leading medical research institution, iBox provides transplant physicians with early insight into complications, significantly enhancing patient outcomes and enabling faster clinical trials. Already integrated into major transplant centers in France and benefiting thousands of patients, Okeiro's platform has been recognized for its medical and economic value through reimbursement by the French National Health Insurance.
This latest funding round will support Okeiro’s ongoing expansion into European markets including the UK, Germany, and Spain, and help prepare for entry into the U.S. market later this year. The capital will also be used to advance development of new AI-driven diagnostic and therapeutic tools tailored for patients with end-stage chronic diseases and those undergoing transplantation."We're grateful to our new investors for their strategic backing in this pivotal growth phase. Backed by our strong science and clinically validated AI models, Okeiro is set to transform transplant medicine globally. We'll deliver on our mission to create a new standard where breakthrough technology elevates patient care while accelerating clinical research for drug development in this critical field” said Pierrick Arnal, CEO and co-founder of Okeiro.
To further validate its technology, Okeiro is currently running a large-scale randomized clinical trial across 16 hospitals in six countries. The study compares the outcomes of patients monitored using the platform with those treated under standard protocols, with interim results already showing promising improvements. Previously known as Predict4Health, the company has rebranded as Okeiro — derived from the Greek "Kairos," meaning "the critical moment" — to reflect its mission of empowering clinicians with timely, life-saving insights.